Orthocell Gains Key Approval for Remplir in Singapore

Orthocell Ltd (AU:OCC) has released an update.

Orthocell Ltd has announced a significant milestone with the regulatory approval of Remplir, their nerve repair product, by Singapore’s Health Sciences Authority, marking the first major international expansion beyond Australia and New Zealand. This approval paves the way for sales in Singapore and acts as a gateway to further ASEAN markets, with a global market opportunity estimated at over US$3.5 billion. The company is also on track for US FDA clearance and is experiencing robust revenue growth in its current markets.

For further insights into AU:OCC stock, check out TipRanks’ Stock Analysis page.